Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Entry Into a Material Definitive Agreement.
On August 11, 2017, Kadmon Holdings, Inc. (the “Company”) and ARE-East River Science Park, LLC (the “Landlord”) entered into Amendment No. 5 (the “Fifth Amendment”) and Amendment No. 6 (the “Sixth Amendment”) to that certain Lease Agreement dated as of October 28, 2010, as amended (the “Lease”).
to the terms of the Fifth Amendment, the Company will surrender 13,475 square feet of laboratory space under the Lease and will make a surrender payment of approximately $1.1 million, which amount shall be offset as set forth below.
to the terms of the Sixth Amendment, the term of the Lease is extended for an additional year through October 28, 2025. The Company will also receive approximately $1.1 million in rent abatement beginning September 1, 2017.
The foregoing summary of the Fifth and Sixth Amendments is not complete and is qualified in its entirety by reference to the full and complete text of the Fifth and Sixth Amendments, copies of which are attached as Exhibit 10.1 and 10.2, respectively, to this Current Report on Form 8-K, which are incorporated herein by reference.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in Item 1.01 above is incorporated by reference into this Item 2.03.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
10.1 |
Amendment # 5 to Lease Agreement, dated August 11, 2017, by and between ARE-East River Science Park, LLC and Kadmon Corporation, LLC. |
|
10.2 |
Amendment # 6 to Lease Agreement, dated August 11, 2017, by and between ARE-East River Science Park, LLC and Kadmon Corporation, LLC. |
Kadmon Holdings, Inc. ExhibitEX-10.1 2 kdmn-20170814xex10_1.htm EX-10.1 ARE Kadmon – Lease Amendment 5 Exhibit 10.1 FIFTH Amendment to Lease This Fifth Amendment to Lease (this “Amendment”) is made as of August 11,…To view the full exhibit click here
About Kadmon Holdings, Inc. (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
